德镁医药递表港交所:高毛利难掩亏损隐忧

DoNews
07 Jun

德镁医药近日向联交所递交上市申请,拟以介绍方式登陆主板,华泰国际担任独家保荐人。作为康哲药业分拆的皮肤业务平台,公司2020年于境外成立,专注于皮肤处方药和护肤品领域。2022年至2024年,其收入从3.84亿元增长至6.18亿元,主要依赖皮肤处方药贡献,但该业务占比逐年下降,护肤品收入逐步提升。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10